Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice

Cardiovascular Research

Volumn 87, Issue 3, 2010, Pages 424-430

  Kobara, Miyuki ^a   Noda, Kazuki ^a   Kitamura, Miho ^a   Okamoto, Akiharu ^a   Shiraishi, Tatsuya ^a   Toba, Hiroe ^a   Matsubara, Hiroaki ^b   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Interleukin 6; Left ventricular remodelling; Myocardial infarction

Indexed keywords

GELATINASE A; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MR16 1; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; UNCLASSIFIED DRUG; CCL2 PROTEIN, MOUSE; MMP2 PROTEIN, MOUSE; NEUTRALIZING ANTIBODY; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; HEART DILATATION; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HISTOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MACROPHAGE; MALE; MONOCYTE; MOUSE; MYOCARDITIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; FIBROSIS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MYOCARDIAL INFARCTION; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ANIMALS; ANTIBODIES, NEUTRALIZING; APOPTOSIS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; FIBROSIS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; NEUTROPHIL INFILTRATION; PEROXIDASE; RECEPTORS, INTERLEUKIN-6; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 77954781995     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq078     Document Type: Article

References (39)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
2. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction; results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
3. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP et al. Valsar-tan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
4. Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P et al. Toler-ability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Car-vedilol ACE-Inhibitor Remodelling Mild CHF Evaluation). Eur J Heart Fail 2004;6: 467-475.
5. Guillén I, Blanes M, Gómez-Lechón MJ, Castell JV. Cytokine signaling during myocar-dial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol 1995;269: R229-R235.
6. Munkvad S, Gram J, Jespersen J. Interleukin-1 and tumor necrosis factor-alpha in plasma of patients with acute ischemic heart disease who undergo thrombolytic therapy: a randomized, placebo-controlled study. Lymphokine Cytokine Res 1991;10: 325-327.
7. Manginas A, Bei E, Chaidaroglou A, Degiannis D, Koniavitou K, Voudris V et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 2005;28:182-186.
8. Ono K, Matsumori A, Furukawa Y, Igata H, Shioi T, Matsushima K et al. Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1999;79: 195-203.
9. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003;108: 2134-2140. (Pubitemid 37337591)
10. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005;96:881-889.
11. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001;38:1546-1553.
12. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-1553.
13. Puhakka M, Magga J, Hietakorpi S, Penttilä I, Uusimaa P, Risteli J et al. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J Card Fail 2003;9:325-332.
14. Ohtsuka T, Hamada M, Inoue K, Ohshima K, Sujzuki J, Matsunaka T et al. Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol 2004;27:417-420.
15. Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is upregu-lated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002;55:329-340.
16. Kaminski KA, Kozuch M, Bonda T, Wojtkowska I, Kozieradzka A, Dobrzycki S et al. Coronary sinus concentrations of interleukin 6 and its soluble receptors are affected by reperfusion and may portend complications in patients with myocardial infarction. Atherosclerosis 2009;206:581-587.
17. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58:573-581.
18. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16: 249-284.
19. Kimura T, Kanda T, Kotajima N, Kuwabara A, Fukumura Y, Kobayashi I. Involvement of circulating interleukin-6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction. Eur J Endocrinol 2000;143: 179-184.
20. Kobara M, Sunagawa N, Abe M, Tanaka N, Toba H, Hayashi H et al. Apoptotic myo-cytes generate monocyte chemoattractant protein-1 and mediate macrophage recruitment. J Appl Physiol 2008;104:601-609.
21. Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 2002;84:231-240.
22. Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-311.
23. Kobara M, Tatsumi T, Kambayashi D, Mano A, Yamanaka S, Shiraishi J et al. Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J Cardiovasc Pharmacol 2003;41:880-889.
24. Zheng W, Weiss RM, Wang X, Zhou R, Arlen AM, Lei L et al. DITPA stimulates arter-iolar growth and modifies myocardial postinfarction remodeling. Am J Physiol Heart Circ Physiol 2004;286:H1994-H2000.
25. Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 2005;112:2812-2820.
26. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD et al. Myeloper-oxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003;197:615-624.
27. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
28. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003;285:H1229-H1235.
29. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocar-dial infarction in mice. J Clin Invest 2005;115:599-609.
30. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106: 55-62.
31. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 1995;92:1866-1875.
32. Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999;99:546-551.
33. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14:705-714.
34. Tomiyama-Hanayama M, Rakugi H, Kohara M, Mima T, Adachi Y, Ohishi M et al. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Am J Physiol Renal Physiol 2009;297:F679-F684.
35. Okada S, Nakamura M, Mikami Y, Shimazaki T, Mihara M, Ohsugi Y et al. Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. J Neurosci Res 2004;76:265-276.
36. Chandrasekar B, Mitchell DH, Colston JT, Freeman GL. Regulation of CCAAT/enhan-cer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion. Circulation 1999;99:427-433.
37. Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J 2003;17:2118-2120.
38. Matsushita K, Iwanaga S, Oda T, Kimura K, Shimada M, Sano M et al. Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 2005;85:1210-1223.
39. Wang F, Trial J, Diwan A, Gao F, Birdsall H, Entman M et al. Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol 2002;34: 1309-1316.